NCT05813223View on ClinicalTrials.gov

Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

June 30, 2026

Conditions

Chronic Cough

Interventions

DRUG

Gefapixant

Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.

Trial Locations (1)

3010

RECRUITING

The University of Melbourne, Parkville

Sponsors

Collaborators (1)

Melbourne Health

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Melbourne Health

OTHER

collaborator

Monash University

OTHER

lead

Stuart Mazzone

OTHER